Search research articles
Contact Us
Filters
Showing results (591-600 of 1,058) with videos related to
Page
of 106
Sort By:
Leukemia
|
October 22, 2005
The evolving role of alemtuzumab in management of patients with CLL
S Faderl, S Coutré, J C Byrd, et al.
Small (Weinheim an Der Bergstrasse, Germany)
|
May 28, 2022
DNA Origami Nanostructures Elicit Dose-Dependent Immunogenicity and Are Nontoxic up to High Doses In Vivo
Christopher R Lucas, Patrick D Halley, Amjad A Chowdury, et al.
Leukemia Research
|
May 31, 2022
ROR1 targeted immunoliposomal delivery of OSU-2S shows selective cytotoxicity in t(1;19)(q23;p13) translocated B-cell acute lymphoblastic leukemia
Swagata Goswami, Chi-Ling Chiang, Kevan Zapolnik, et al.
Cancer Genetics and Cytogenetics
|
December 16, 2010
Progressive but previously untreated CLL patients with greater array CGH complexity exhibit a less durable response to chemoimmunotherapy
Neil E Kay, Jeanette E Eckel-Passow, Esteban Braggio, et al.
Leukemia
|
February 1, 2012
Outcome of patients with relapsed or refractory chronic lymphocytic leukemia treated with flavopiridol: impact of genetic features
J A Woyach, G Lozanski, A S Ruppert, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences
|
January 27, 2007
Liquid chromatography mass spectrometry profiling of histones
Xiaodan Su, Naduparambil K Jacob, Ravindra Amunugama, et al.
Molecular Biosystems
|
October 9, 2012
Elucidating role of salivary proteins in denture stomatitis using a proteomic approach
Sompop Bencharit, Sandra K Altarawneh, Sarah Schwartz Baxter, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 30, 1999
Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered
J C Byrd, R K Dodge, A Carroll, et al.
Blood
|
November 25, 2010
Silencing of the inhibitor of DNA binding protein 4 (ID4) contributes to the pathogenesis of mouse and human CLL
Shih-Shih Chen, Rainer Claus, David M Lucas, et al.
Mabs
|
March 6, 2014
Ocaratuzumab, an Fc-engineered antibody demonstrates enhanced antibody-dependent cell-mediated cytotoxicity in chronic lymphocytic leukemia
Carolyn M Cheney, Deborah M Stephens, Xiaokui Mo, et al.
Page
of 106
Search research articles
Search
Showing results (591-600 of 1,058) with videos related to
Sort By:
Page
of 106
Leukemia
|
October 22, 2005
The evolving role of alemtuzumab in management of patients with CLL
S Faderl, S Coutré, J C Byrd, et al.
Small (Weinheim an Der Bergstrasse, Germany)
|
May 28, 2022
DNA Origami Nanostructures Elicit Dose-Dependent Immunogenicity and Are Nontoxic up to High Doses In Vivo
Christopher R Lucas, Patrick D Halley, Amjad A Chowdury, et al.
Leukemia Research
|
May 31, 2022
ROR1 targeted immunoliposomal delivery of OSU-2S shows selective cytotoxicity in t(1;19)(q23;p13) translocated B-cell acute lymphoblastic leukemia
Swagata Goswami, Chi-Ling Chiang, Kevan Zapolnik, et al.
Cancer Genetics and Cytogenetics
|
December 16, 2010
Progressive but previously untreated CLL patients with greater array CGH complexity exhibit a less durable response to chemoimmunotherapy
Neil E Kay, Jeanette E Eckel-Passow, Esteban Braggio, et al.
Leukemia
|
February 1, 2012
Outcome of patients with relapsed or refractory chronic lymphocytic leukemia treated with flavopiridol: impact of genetic features
J A Woyach, G Lozanski, A S Ruppert, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences
|
January 27, 2007
Liquid chromatography mass spectrometry profiling of histones
Xiaodan Su, Naduparambil K Jacob, Ravindra Amunugama, et al.
Molecular Biosystems
|
October 9, 2012
Elucidating role of salivary proteins in denture stomatitis using a proteomic approach
Sompop Bencharit, Sandra K Altarawneh, Sarah Schwartz Baxter, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 30, 1999
Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered
J C Byrd, R K Dodge, A Carroll, et al.
Blood
|
November 25, 2010
Silencing of the inhibitor of DNA binding protein 4 (ID4) contributes to the pathogenesis of mouse and human CLL
Shih-Shih Chen, Rainer Claus, David M Lucas, et al.
Mabs
|
March 6, 2014
Ocaratuzumab, an Fc-engineered antibody demonstrates enhanced antibody-dependent cell-mediated cytotoxicity in chronic lymphocytic leukemia
Carolyn M Cheney, Deborah M Stephens, Xiaokui Mo, et al.
Page
of 106